Specifically, targeting CLC3 and its regulatory effects on V-ATPase could disrupt the lysosomal functions that are vital for cancer cell survival under chemotherapy, thereby enhancing the efficacy of existing treatments. The gene discussed is CLCN3; the disease is cancer.